Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update

Silo Pharma, Inc. (NASDAQ:SILO) saw a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 33,208 shares, a drop of 60.0% from the August 15th total of 82,948 shares. Based on an average trading volume of 206,120 shares, the days-to-cover ratio is currently 0.2 days. Approximately 2.2% of the shares of the company are short sold.

Institutional Trading of Silo Pharma

An institutional investor recently raised its stake in Silo Pharma stock. AdvisorShares Investments LLC grew its stake in shares of Silo Pharma, Inc. (NASDAQ:SILO) by 10.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 663,965 shares of the company’s stock after buying an additional 64,458 shares during the period. AdvisorShares Investments LLC owned 4.08% of Silo Pharma worth $239,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.58% of the company’s stock.

Silo Pharma Trading Down 1.4%

SILO stock traded down $0.03 during trading on Monday, hitting $2.07. 28,724 shares of the company traded hands, compared to its average volume of 123,553. The company has a 50-day moving average of $3.73 and a 200-day moving average of $5.23. Silo Pharma has a 1 year low of $2.05 and a 1 year high of $15.15.

Silo Pharma (NASDAQ:SILO) last posted its earnings results on Thursday, August 13th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.44). Silo Pharma had a negative return on equity of 81.75% and a negative net margin of 6,726.39%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Silo Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Silo Pharma Company Profile

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.